This paper reviews data on the natural history of symptoms in patients with Alzheimer's disease (AD) and describes some of the problems encountered in analysing longitudinal data in this population. Data on cognition, functional ability and psychiatric or behavioural symptoms have all been obtained
Measuring cognitive change in a cohort of patients with Alzheimer's disease
โ Scribed by Douglas R. Galasko; Robert L. Gould; Ian S. Abramson; David P. Salmon
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- English
- Weight
- 133 KB
- Volume
- 19
- Category
- Article
- ISSN
- 0277-6715
No coin nor oath required. For personal study only.
โฆ Synopsis
Annualized rates of cognitive change in Alzheimer's disease (AD), an important index of disease progression, show marked variability. To determine factors leading to such variability, we computed rates of change in a cohort of patients with AD tested annually with the Mini Mental State Examination (MMSE) and the more detailed Dementia Rating Scale (DRS). Estimates of rates of change (slopes) and intercepts were calculated using least squares and best linear unbiased predictors (BLUPs). Potential predictors of rates of change were examined using multivariate linear regression analysis. We found that the MMSE had more noise than the DRS. For the MMSE, slopes showed a moderate oor e ect and a slight ceiling, depending on initial MMSE scores. These e ects were less prominent for the DRS, for which slopes increased as intercepts decreased. In analyses of predictors of change, the MMSE was less useful than the DRS. In multiple linear regression models using DRS data, predictors showed statistically stronger e ects and explained a greater extent of variation of slopes than did similar models using MMSE data. For example, among patients who died and underwent brain examination at autopsy, neuropathology of Lewy bodies plus AD (Lewy Body variant; LBV) was associated with signiรฟcantly faster rates of cognitive decline compared to pure AD in analyses that used the DRS, but only trends were identiรฟed with the MMSE. The metric properties and longitudinal characteristics of cognitive tests and the statistical methods used to calculate change are key factors in obtaining reliable estimates of change in studying cohorts of patients with AD.
๐ SIMILAR VOLUMES
A large number of experimental compounds are being developed for the treatment of patients with Alzheimer's disease (AD). As dierent compounds may have dierent eects on CNS function, depending on which neurotransmitters they aect, adequate proยฎling will require the use of several tests. The dicultie
Patients with Alzheimer's disease (AD) and their families must confront two fundamental truths. First, AD is a uniformly progressive disease that ultimately results in debilitating cognitive impairment. Second, although there is now evidence that some medications may produce transient improvement or
Dementia is characterized by accelerated cognitive decline before and after diagnosis as compared to normal ageing. Determining the time at which that rate of decline begins to accelerate in persons who will develop dementia is important both in describing the natural history of the disease process
The psychometric properties of the Beck Depression Inventory (BDI) in subjects with Alzheimer's disease (AD) and depression have not been fully evaluated. Item endorsement patterns may be distorted by the presence of AD. This was tested by applying the BDI to a sample of 129 subjects with probable A